Cargando…
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
PD-L1(+) tumor-derived extracellular vesicles (TEVs) cause systemic immunosuppression and possibly resistance to anti-PD-L1 antibody (αPD-L1) blockade. However, whether and how PD-L1(+) TEVs mediate αPD-L1 therapy resistance is unknown. Here, we show that PD-L1(+) TEVs substantially decoy αPD-L1 and...
Autores principales: | Chen, Jiming, Yang, Jie, Wang, Wenhui, Guo, Danfeng, Zhang, Chengyan, Wang, Shibo, Lu, Xinliang, Huang, Xiaofang, Wang, Pingli, Zhang, Gensheng, Zhang, Jing, Wang, Jianli, Cai, Zhijian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622748/ https://www.ncbi.nlm.nih.gov/pubmed/36220994 http://dx.doi.org/10.1038/s41423-022-00926-6 |
Ejemplares similares
-
Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
por: Mishra, Surbhi, et al.
Publicado: (2022) -
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015) -
Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020) -
Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
por: Zhang, Yiru, et al.
Publicado: (2023) -
Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)